Literature DB >> 315065

Distribution of 5'-nucleotidase in human lymphoid tissues.

N L Edwards, E W Gelfand, L Burk, H M Dosch, I H Fox.   

Abstract

Low activity of 5'-nucleotidase (5'-ribonucleotide phosphohydrolase, EC 3.1.3.5) in T lymphoblasts may explain the marked sensitivity of this cell to deoxynucleotide accumulation when compared to B lymphoblasts. The relevance of such observations with cultured cells to the normal immune system requires the demonstration of similar differences in the 5'-nucleotidase activity of normal human lymphocyte subpopulations. Sheep erythrocyte (E) rosette-forming cells from normal thymus, tonsil, and peripheral mononuclear cells have 5'-nucleotidase activities of 1.7, 11.3, and 21.2 nmol/hr per 10(6) cells. Non-E-rosette forming cells from the peripheral blood or tonsil have 5'-nucleotidase activity comparable to the higher levels found in the peripheral E-RFC. Increased levels of 5'-nucleotidase activity may be a marker for post-thymic T lymphocytes. T lymphoblasts have 5'-nucleotidase activity similar to values demonstrated for E-RFC in thymus, whereas cultured B lymphoblasts have 5'-nucleotidase activity 15 times greater than that of T lymphoblasts. On the basis of these observations, the 5'-nucleotidase deficiency in congenital agammaglobulinemia has been reevaluated. In these patients the data indicate that peripheral E-rosette forming cells have the enzyme deficiency, demonstrating an abnormality of T lymphocytes in this disorder of immunoglobulin production.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 315065      PMCID: PMC383848          DOI: 10.1073/pnas.76.7.3474

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Functional differentiation of B lymphocytes in agammaglobulinemia. III. Characterization of spontaneous suppressor cell activity.

Authors:  H M Dosch; E W Gelfand
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

2.  Purine metabolism in lymphocytes from patients with primary hypogammaglobulinaemia.

Authors:  A D Webster; M North; J Allsop; G L Asherson; R W Watts
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

3.  Lymphocyte ecto-5'-nucleotidase deficiency in agammaglobulinemia.

Authors:  N L Edwards; D B Magilavy; J T Cassidy; I H Fox
Journal:  Science       Date:  1978-08-18       Impact factor: 47.728

4.  5'-Nucleotidase activity in subpopulations of rat lymphocytes.

Authors:  R W Barton; I Goldschneider
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

5.  Radioimmunoassay for human thymus-leukemia-associated antigen.

Authors:  B E Chechik; A Madapallimattam; E W Gelfand
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

6.  Lymphocyte purine 5'-nucleotidase edficiency in primary hypogammaglobulinaemia.

Authors:  S M Johnson; M E North; G L Asherson; J Allsop; R W Watts; A D Webster
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

7.  Surface localization of 5'-nucleotidase on the mouse lymphocyte.

Authors:  R J Uusitalo; M J Karnovsky
Journal:  J Histochem Cytochem       Date:  1977-02       Impact factor: 2.479

8.  Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase.

Authors:  R L Wortmann; B S Mitchell; N L Edwards; I H Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

9.  Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.

Authors:  B S Mitchell; E Mejias; P E Daddona; W N Kelley
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

10.  Purification of human monocytes on microexudate-coated surfaces.

Authors:  S K Ackerman; S D Douglas
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

View more
  22 in total

1.  Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells.

Authors:  M Massaia; U Dianzani; P Pioppo; E Sibilla; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

Review 2.  5'-Nucleotidase: molecular structure and functional aspects.

Authors:  H Zimmermann
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

Review 3.  Heberden oration 1979: human aberrations of purine metabolism and their significance for rheumatology.

Authors:  J E Seegmiller
Journal:  Ann Rheum Dis       Date:  1980-04       Impact factor: 19.103

4.  Adenosine deaminase and 5'nucleotidase activities in peripheral blood T cells of multiple sclerosis patients.

Authors:  S Vivekanandhan; C C Soundararajan; M Tripathi; M C Maheshwari
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

5.  Correlations between enzymatic and immunologic properties of human peripheral blood mononuclear cells. I. Ectoenzymes of normal and immunodeficient peripheral blood mononuclear cells.

Authors:  G Losa; A Morell; S Barandun
Journal:  Am J Pathol       Date:  1982-05       Impact factor: 4.307

6.  Kinetic properties of 5' nucleotidase in blood lymphocytes from healthy subjects, immunodeficient patients and cord blood.

Authors:  T Shah; A D Webster; T J Peters
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

7.  Enzymes of purine metabolism in human peripheral lymphocyte subpopulations.

Authors:  M Massaia; D D Ma; T A Sylwestrowicz; N Tidman; G Price; G Janossy; A V Hoffbrand
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

8.  Independent expression of the surface markers 5'-nucleotidase and cALLA on leukemic cells.

Authors:  W Gutensohn; B Wünsch; H Rodt
Journal:  Blut       Date:  1983-04

9.  Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.

Authors:  J J Hutton; D A Wiginton; M S Coleman; S A Fuller; S Limouze; B C Lampkin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

10.  Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy.

Authors:  S L Sacks; T C Merigan; J Kaminska; I H Fox
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.